Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPH-105
- Development stage
- Preclinical
- Lead developer
- Sapphire Therapeutics
- Administration
- Rectal
01
Overview
SPH-105 is an investigational, discovery-stage therapeutic candidate being developed by Sapphire Therapeutics for the treatment of ulcerative proctitis. Designed for rectal administration, the drug utilizes a non-immunosuppressive approach by targeting a novel, undisclosed receptor that modulates the NFkB and IL-22 signaling pathways. This mechanism is intended to promote mucosal healing and resolve inflammation in the rectum without the systemic side effects typically associated with traditional immunosuppressive therapies for inflammatory bowel disease.
Beyond the preview
Go deeper on SPH-105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPH-105.